16 February 2024 Initial COBRA results: Clarity’s SAR-bisPSMA is safe and highly effective in detecting tumours in prostate cancer patients. Phase 3 planning underway. 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post